The transcatheter mitral valve replacement (TMVR) market is projected to grow at a CAGR of 20% over the forecast period. Major factors driving growth include increased prevalence of mitral valve diseases, growing preferences for minimally invasive procedures, advancements in TMVR technology, growing geriatric population, increasing clinical trials & regulatory approvals for TMVR devices, and favorable reimbursement policies for TMVR procedures.
Transcatheter Mitral Valve Replacement (TMVR) is a minimally invasive procedure designed to replace a damaged or diseased mitral valve in the heart. As one of the four heart valves regulating blood flow between chambers, the mitral valve plays a crucial role in circulation. When it becomes compromised, it can lead to blood leakage into the lungs, causing symptoms such as shortness of breath, fatigue, and fluid buildup.
During TMVR, a new valve is delivered through a catheter, typically inserted via an artery in the groin or chest. Using advanced imaging techniques like X-ray or echocardiography, the catheter is carefully guided to the heart. Once positioned, the new valve is expanded and secured within the existing valve structure, restoring proper blood flow.
TMVR can be performed using two main techniques:
β’ Native Valve Replacement: An investigational approach that directly replaces the patientβs original mitral valve
β’ Valve-in-Valve Replacement: A method used to implant a new valve within a failing prosthetic valve or a previously placed annuloplasty ring from prior surgery.
π Want deeper insights? Download the sample report here:
https://meditechinsights.com/transcatheter-mitral-valve-replacement-tmvr-market/request-sample/
The increasing prevalence of mitral valve diseases drives market growth
The increasing prevalence of mitral valve diseases, particularly mitral regurgitation (MR) and mitral stenosis (MS), is becoming a significant global health concern. Factors such as an aging population, rising incidences of cardiovascular diseases, and lifestyle-related conditions like hypertension and obesity contribute to the growing burden of these disorders. A 2023 ScienceDirect article states that mitral regurgitation, the most prevalent valvular heart disease, impacts approximately 2% of the general population and up to 10% of individuals over 75, frequently resulting in heart failure if untreated. Additionally, mitral stenosis remains a major issue in developing regions due to persistent cases of rheumatic heart disease. Many of these conditions progress silently, resulting in late-stage diagnosis and the need for advanced interventions. As surgical treatments pose high risks for elderly and comorbid patients, the demand for minimally invasive solutions such as transcatheter mitral valve replacement (TMVR) is rising, driving innovation and growth in the global TMVR market.
Growing preference for minimally invasive procedures in TMVR fuels its demand
The growing preference for minimally invasive procedures in transcatheter mitral valve replacement (TMVR) is transforming the landscape of mitral valve disease treatment. Unlike traditional open-heart surgery, which involves significant risks, long recovery times, and potential complications, TMVR offers a less invasive alternative with reduced hospital stays and faster patient recovery. Advancements in catheter-based technology, imaging guidance, and procedural techniques have made TMVR a viable option for high-risk patients who are ineligible for conventional surgery. Additionally, the increasing awareness of patient-centric care and the demand for quicker, less painful treatments are driving the adoption of minimally invasive TMVR. As healthcare systems prioritize cost-effective solutions with better clinical outcomes, the shift toward minimally invasive interventions is expected to accelerate, further boosting the growth of the TMVR market.
Competitive Landscape Analysis
The global transcatheter mitral valve replacement (TMVR) market is marked by the presence of established and emerging market players such as Abbott Laboratories; Edwards Lifesciences; Medtronic plc; Boston Scientific Corporation; LivaNova; Cardiac Dimensions; NeoChord, Inc.; Opus Medical Therapies, LLC; HighLife Medical; and Neovasc; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and investments.
Get PDF Report for Competitive Analysis:
https://meditechinsights.com/transcatheter-mitral-valve-replacement-tmvr-market/request-sample/
Market Segmentation
This report by Medi-Tech Insights provides the size of the global transcatheter mitral valve replacement (TMVR) market at the regional- and country level from 2023 to 2030. The report further segments the market based on product type, indication, and end user.
β’ Market Size & Forecast (2023-2030), By Product Type, USD Million
o Mechanical Valves
o Bioprosthetic/Tissue Valves
β’ Market Size & Forecast (2023-2030), By Indication, USD Million
o Functional Mitral Regurgitation (FMR)
o Degenerative Mitral Regurgitation (DMR)
β’ Market Size & Forecast (2023-2030), By End User, USD Million
o Hospitals
o Ambulatory Surgical Centers (ASCs)
o Cardiac Catheterization Laboratories
o Others
β’ Market Size & Forecast (2023-2030), By Region, USD Million
o North America
ο§ US
ο§ Canada
o Europe
ο§ UK
ο§ Germany
ο§ France
ο§ Italy
ο§ Spain
ο§ Rest of Europe
o Asia Pacific
ο§ China
ο§ India
ο§ Japan
ο§ Rest of Asia Pacific
o Latin America
o Middle East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
[email protected]
Top comments (0)